Evidence map›Paper›PMID 42473063›Full record

GuidelineInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026

FIGO staging for gestational trophoblastic neoplasia: 2026.

Hextan Y S Ngan, Michael J Seckl, Neil Horowitz, Annie N Y Cheung, Antonio Braga, Paradan K Sekharan, Susanne Fridsten, Andrea Garrett, Nozomu Yanaihara, Sarikapan Wilailak and 1 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Rare Case of Multimetastatic Choriocarcinoma.Diagnostics (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hextan Y S NganDepartment of Obstetrics and Gynecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Michael J SecklDepartment of Medical Oncology, Charing Cross Trophoblastic Disease Center, Charing Cross Campus of Imperial College London, London, UK.
Neil HorowitzDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Annie N Y CheungDepartment of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Antonio BragaDepartment of Obstetrics and Gynecology, Rio de Janeiro Federal University. Federal University of the State of Rio de Janeiro. Vassouras University, Rio de Janeiro, Brazil.
Paradan K SekharanDepartment of Obstetrics and Gynecology, Institute of Maternal and Child Health, Medical College, Calicut, India.
Susanne FridstenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Andrea GarrettDepartment of Gynecologic Oncology, Women's and Newborn Services, Queensland Trophoblast Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Nozomu YanaiharaDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Sarikapan WilailakDepartment of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Barbara SchmalfeldtClinic and Polyclinic for Gynecology, University Medical Center Hamburg-Eppendorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gestational trophoblastic neoplasia (GTN) encompasses a wide range of diseases, which include choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor, and post-molar persistent or rising levels of human chorionic gonadotrophin. Standardization of the diagnostic criteria and investigative approaches for this uncommon, potentially lethal, yet highly treatable disease is important. Adoption of an evidence-based staging and scoring system is essential to guide patient management and enable comparison of treatment outcomes. An updated staging system for GTN has been proposed and adopted by the Committee on Women's Cancer of the International Federation of Gynecology and Obstetrics (FIGO) for this purpose. This article highlights the changes introduced in the 2026 system and provide explanatory notes to facilitate interpretation.

Indexed as

Gestational Trophoblastic DiseaseNeoplasm StagingChoriocarcinomaFemaleHumansPregnancyUterine Neoplasmschoriocarcinomaepithelioid trophoblastic tumorFIGO cancer reportgestational trophoblastic diseasegestational trophoblastic neoplasiahydatidiform moleplacental site trophoblastic tumor

Identifiers

PMID42473063
PMCPMC13505264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.